RxDoctor Payments Data

Nina McKernan

Family · Albuquerque, NMNPI 1962176354

Payments from drug & device makers

$810in general payments, 2019–2025

Across 32 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • Edwards Lifesciences$146
  • Boehringer Ingelheim$116
  • Lilly USA, LLC$97
  • Pfizer$49
  • Novartis$43
  • plus $161 from 9 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 75th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$8,765
Medicare patients
43
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$22,840
JanuviaSitagliptin Phosphate13$8,604
Levothyroxine Sodium163$2,123
Atorvastatin Calcium134$1,461
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,422
Rosuvastatin Calcium87$1,266
Losartan Potassium112$1,116
Albuterol Sulfate HfaAlbuterol Sulfate31$979
Duloxetine Hcl50$707
Gabapentin63$681
Omeprazole74$678
Tamsulosin Hcl21$566
Lisinopril95$561
Amlodipine Besylate65$556
Allopurinol25$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$116$22,84028 claims
MerckJanuvia$12$8,60413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →